Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of int… Read full Trend Edge analysis →
| Current Price | $16.43 |
|---|---|
| Market Cap | $787M |
| Float | 11.6M |
| Shares Outstanding | 47.2M |
| Price/Sales (TTM) | 263.61 |
| Operating Margin (TTM) | -10739.72% |
| Revenue (TTM) | $3.0M |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2022 | N/A | -$125M | N/A | N/A |
| 2023 | $1.0M | -$126M | N/A | N/A |
| 2024 | $4.5M | -$129M | N/A | N/A |
| 2025 | $3.0M | -$149M | N/A | N/A |
| Quarter | Revenue | Net Income |
|---|---|---|
| Dec 2024 | $1.8M | -$35.9M |
| Insider Ownership | 2.0% |
|---|---|
| Institutional Ownership | 38.4% |
| Short Float | 0.7% |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $0.00 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $0.00 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $0.00 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | N/A | N/A | N/A | N/A | N/A |
| 1 Day | N/A | N/A | N/A | N/A | N/A |
| 1 Week | N/A | N/A | N/A | N/A | N/A |
| 2 Weeks | N/A | N/A | N/A | N/A | N/A |
| 1 Month | N/A | N/A | N/A | N/A | N/A |
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 38.4%
Total insider ownership: 2.0%
| Total Filings | 7 |
|---|---|
| Net Value | +$20,000 |
| Net Shares Change | 13,175,092 |
| % of Float | 113.6% |
| C-Suite Filings | 1 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| TPG GP A, LLC | +$25.0M | 1 | 1 buy | |
| Dimension Capital II, L.P. | +$20.0M | 1 | 1 buy | |
| Li Nan (LN) | +$20.0M | 1 | 1 buy | |
| SR ONE CAPITAL MANAGEMENT, LLC | +$10.0M | 1 | 1 buy, 1 sell | |
| Chu Shelley | +$199,998 | 1 | 1 buy | |
| LEIDEN JEFFREY M | +$99,694 | 1 | 1 buy | |
| Haas Jason | Chief Financial Officer | +$20,000 | 1 | 1 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-05-11 – 2026-05-13 | 7 | 7 | +$75.2M | 1 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | +$10.0M | Transaction at $18.00, now -8.7% | |
| 2026-05-11 | Haas Jason | Chief Financial Officer | +$20,000 | Transaction at $20.00, now -17.9% |
| 2026-05-12 | Dimension Capital II, L.P. | +$20.0M | Transaction at $18.00, now -8.7% | |
| 2026-05-11 | Li Nan (LN) | +$20.0M | Transaction at $18.00, now -8.7% | |
| 2026-05-11 | LEIDEN JEFFREY M | +$99,694 | Transaction at $19.00, now -13.5% | |
| 2026-05-11 | Chu Shelley | +$199,998 | Transaction at $18.00, now -8.7% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Odyssey Therapeutics, Inc. Common Stock (ODTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for ODTX on Trend Edge →